Social Media Ideas for Agerion

Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.

Apogee Therapeutics: Targeting Atopic Dermatitis

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare H...

ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect

As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche hel...

Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

CVS obesity drug deal puts Lilly on equal footing with Novo

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. 

<![CDATA[Pharmaceutical Executive Daily: The Medicare GLP-1 Bridge]]>

Sanofi's Nexviazyme hits primary goal in Pompe disease study

A Metabolic Disease Posing Severe Pancreatic Risks Gets Its First FDA-Approved Therapy

Ionis Pharmaceuticals’ Tryngolza is now the first approved therapy for treating severe hypertriglyceridemia, a prevalent chronic metabolic disorder that can lead to acute pancreati...

<![CDATA[Pharmaceutical Executive Daily: Alnylam Pharmaceuticals and Inceptive Nucleics Announce 3 Year Strategic Col...

<![CDATA[Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics]]>

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare H...

<![CDATA[AbbVie to Acquire Apogee Therapeutics in $10 Billion Deal]]>

Nortiva purrs into action with long-acting Lynx platform salvaged from Langer startup

Innoviva has revealed the next steps for Langer Lab assets it rescued from Lyndra Therapeutics’ collapse, launching Nortiva Bio to develop long-acting oral medicines and pursue dru...

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. 

<![CDATA[Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion]]>

FDA approves Tryngolza to reduce acute pancreatitis risk

The FDA has approved olezarsen as the first and only therapy, alongside diet, to lower triglycerides and acute pancreatitis risk in patients with severe hypertriglyceridemia, accor...

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted i...

<![CDATA[Novartis to Acquire Myricx Bio for $1.1 Billion]]>

Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover

Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, setting the Swiss drugmaker up to talk to global regulatory agencies abou...

Apellis Acquisition

Apellis Acquisition Anonymous (not verified) Sat, 07/11/2026 - 09:12 field_thread_url https://cafepharma.com/boards/threads/apellis-acquisition.715869/...

Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio